The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market At The End Of The 2026–2030 Forecast Period?
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market has demonstrated steady expansion in recent years. It is anticipated to grow from $1.31 billion in 2025 to $1.37 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.6%. The historical growth in this market can be attributed to factors such as the limited availability of targeted therapies, a dependence on conventional chemotherapy and radiation therapy, low awareness regarding her2-positive gastric cancer, restricted access to specialty clinics, and the gradual adoption of immunotherapy.
The market for human epidermal growth factor receptor 2 (her2)-positive gastric cancer is anticipated to experience consistent expansion over the upcoming years. This market is projected to reach $1.64 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.6%. Factors contributing to this expansion during the forecast period include the development of innovative antibody-drug conjugates, a rise in clinical trials for her2-targeted treatments, improvements in healthcare infrastructure within emerging markets, advancements in precision medicine and biomarker testing, and the proliferation of ambulatory surgery centers and specialized oncology clinics. Key trends anticipated for the forecast period encompass a greater acceptance of her2-targeted therapies, heightened awareness regarding gastric cancer subtypes, broader application of immunotherapy and monoclonal antibodies, an increase in personalized treatment strategies, and a stronger emphasis on early detection and diagnostic procedures.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25787&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
The increasing integration of targeted cancer therapy is projected to stimulate growth within the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market moving forward. This therapeutic approach, also known as personalized medicine, utilizes specific drugs or substances to impede cancer development by focusing on particular molecules involved in tumor formation. The surge in targeted therapy use largely stems from breakthroughs in genetic profiling, which facilitate more precise treatments tailored to an individual’s unique tumor characteristics, leading to enhanced effectiveness and fewer side effects. For HER2-positive gastric cancer, targeted therapy functions by directly attacking the HER2 protein, which is overexpressed in these tumors, thereby slowing disease progression and improving patient outcomes. For instance, in February 2024, data from the Personalized Medicine Coalition, a US-based professional membership organization, indicated that the Food and Drug Administration (FDA) approved 16 new personalized medicines in 2023, including 7 drugs for cancer and 3 for various other diseases and conditions, showing an increase from 6 approvals in 2022. As a result, the growing adoption of targeted cancer therapy is propelling the expansion of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market.
What Segment Types Make Up The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy
2) By Stage: Stage I, Stage II, Stage III, Stage IV
3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines
2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies
3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy
4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors
Which Market Trends Are Creating New Opportunities In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
Major companies operating in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market are prioritizing securing approvals for innovative therapies, such as advanced immunotherapy-enhanced combination regimens. These regimens, which integrate immune checkpoint inhibitors with targeted therapy and chemotherapy, are designed to significantly improve patient outcomes in first-line treatment settings. The advanced immunotherapy-enhanced combination regimens approach functions by engaging the body’s immune system through the inhibition of programmed death (PD)-1 or programmed death (PD)-L1 interaction, concurrently targeting HER2 receptors, and utilizing chemotherapeutic agents, thereby intensifying anti-tumor activity and improving survival rates. For example, in March 2025, Merck & Co., Inc., a US-based biopharmaceutical company, received authorization from the U.S. Food and Drug Administration (FDA) for pembrolizumab (Keytruda), combined with trastuzumab and chemotherapy, as a primary treatment for adults with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death (PD)-L1. This newly approved combination therapy showcased a substantial enhancement in median progression-free survival and overall survival compared to existing standard regimens. Boasting a higher overall response rate of 73% and a prolonged median duration of response, this treatment marks a significant advancement in addressing advanced HER2-positive gastric cancers.
Who Are The Key Players Driving Competition In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.
Read the full human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report here:
Which Regions Are Projected To Dominate The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In The Coming Years?
North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25787&type=smp
Browse Through More Reports Similar to the Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market 2026, By The Business Research Company
Gastric Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
Gastric Cancer Diagnostic Procedure Market Report 2026
Intestine Cancer Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model